Contrave, a weight-loss medication, was denied approval by the FDA in January of this year. Contrave, a combination of naltrexone and wellbutrin, had been studied in 4500 patients. However, the FDA noted concern about the cardiovascular safety profile of the medication when used long-term in a population of overweight and obese subjects. The FDA is asking for more studies to evaluate the risk/benefit ratio of the drug.
Despite the denial of Contrave, research on anti-obesity drugs still continues. Along with lifestyle change, anti-obesity drugs do play a role in helping some individuals lose and maintain their weight. The cornerstone of treatment for obesity is still behavior modification, better nutrition, and increased physical activity!